Document ID: chunk:federal_register_of_legislation:F2025C00124:clause:3_1:p253
Version: federal_register_of_legislation:F2025C00124
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 253/476)
Character Range: 2408237–2416181

a unit.
                                                                                                                                            Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.
                                                                                                                                            Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily.
                                                                                                                                            To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment:
                                                                                                                                            (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND
                                                                                                                                            (2) the patient or the patient's family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.
                                                                                                                                            Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.
                                                                       C7367                                                                Cystic fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures ‑ Streamlined Authority Code 7367
                                                                                                                                            The treatment must be in combination with dornase alfa; AND
                                                                                                                                            Patient must be inadequately responsive to dornase alfa; AND
                                                                                                                                            Patient must have trialled hypertonic saline for this condition.
                                                                                                                                            Patient must be 6 years of age or older.
                                                                                                                                            Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved Product Information initiation dose assessment for this drug, prior to therapy with this drug, with a negative result.
                                                                                                                                            Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.
                                                                                                                                            Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.
                                                                                                                                            Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily.
                                                                                                                                            To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment:
                                                                                                                                            (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND
                                                                                                                                            (2) the patient or the patient's family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.
                                                                                                                                            Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.
                                                                       C9527                                                                Cystic fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures ‑ Streamlined Authority Code 9527
                                                                                                                                            The treatment must be as monotherapy; AND
                                                                                                                                            Patient must be intolerant or inadequately responsive to dornase alfa.
                                                                                                                                            Patient must be 6 years of age or older.
                                                                                                                                            Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved